fda status of bpc 157 2024 FDA's Overreach on Compounded Peptides FDA removes BPC-157, KPV, Semax

But that process is slow, incomplete, and often produces scar tissue instead of healthy connective tissue

Mild reactions are very common and come in the form of a lump or swelling around the site of the injection

Then when the engine begins to alternate between coughing, sputtering and blowing smoke and turning off altogether, true-blue, knock you down fatigue sets in

This is why GHK-Cu solutions may turn greenish-blue over time at room temperature - the copper is oxidizing

Gray-market peptides can create risks beyond the peptide itself, raising concerns over product quality, purity, and inconsistent formulation

Risling M